Abstracts tagged "Disease Activity"

Abstract Number: 1371 • 2014 ACR/ARHP Annual Meeting
Impact of Metabolic Syndrome (MetS) on Rheumatoid Arthritis Disease Activity
Federico Parra-Salcedo¹, Irazú Contreras-Yáñez², Daniel Elías-López³, Carlos A. Aguilar-Salinas³ and Virginia Pascual-Ramos⁴, ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán., Mexico City, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose The purpose of the study was to describe prevalence and components (c) of MetS in a cohort of early RA, to compare it with…
Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of NNC01140006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Juan D. Cañete¹, Piotr Leszczynski², Rikke Riisbro³ and Klaus S. Frederiksen³, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, ³Novo Nordisk A/S, Søborg, Denmark
Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…
Abstract Number: 589 • 2014 ACR/ARHP Annual Meeting
Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Lennart TH Jacobsson¹, Tomas Husmark², Elke Theander³, Kenneth Henriksson⁴, Katharina Büsch⁵ and Martin Johansson⁵, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Rheumatology city clinic, Stockholm, Sweden, Stockholm, Sweden, ⁵AbbVie AB, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose The ASAS axial SpA classification criteria was published in 2009 but so far there has been limited research on axial SpA patients in clinical…
Abstract Number: 387 • 2014 ACR/ARHP Annual Meeting
Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Caroline Grönwall¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M. Clancy⁴ and Gregg J. Silverman¹, ¹Medicine, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Monitoring disease activity in patients with autoimmune rheumatic disease is an essential part of clinical care. Highly reactive malondialdehyde (MDA) arise from reactive oxygen…
Abstract Number: L17 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Rheumatoid Arthritis Disease Activity, Reduces Inflammatory Markers, and Decreases Medication Usage
Jeffrey A. Sparks¹, Florencia Halperin², Jonathan C. Karlson³, Elizabeth W. Karlson¹ and Bonnie L. Bermas¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Obesity causes a chronic inflammatory state. Increased body mass index (BMI) is associated with incident rheumatoid arthritis (RA) and may impact RA disease activity.…
Abstract Number: 2973 • 2014 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis
Eric H. Sasso¹, George Wu², CC Hwang², Michael E. Weinblatt³, Nancy A. Shadick⁴, Claire Alexander⁵ and Oscar Segurado¹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ³Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose This study evaluated the association between baseline disease activity, as assessed with the multi-biomarker disease activity (MBDA) blood test, CRP or clinical measures, and…
Abstract Number: 2579 • 2014 ACR/ARHP Annual Meeting
How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? – an Analysis in the DESIR Cohort
Pedro Machado^1,2, Victoria Navarro-Compán^1,3, Robert Landewé^4,5, Floris van Gaalen¹, Christian Roux⁶ and Desirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University College London, London, United Kingdom, ³University Hospital La Paz, Madrid, Spain, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite measure of disease activity in axial spondyloarthritis. It was suggested that when the conventional …
Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…
Abstract Number: 1841 • 2014 ACR/ARHP Annual Meeting
Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, Josh Dixey⁴, Patrick Kiely⁵, David Walsh^6,7 and Adam Young^1,8, ¹School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Institute of Psychiatry, King's College London, London, United Kingdom, ⁴Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁵Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: It is well-established that sustained high disease activity in RA results in worse outcomes. In reality many patients remain in low/moderate disease activity states,…
Abstract Number: 1355 • 2014 ACR/ARHP Annual Meeting
Population Management of Rheumatoid Arthritis (RA) in Rheumatology Practices: A Quality Improvement Project
David Sikes¹, Gary Crump², Kathleen Thomas³, Alex Bangs⁴ and J. Timothy Harrington⁵, ¹Rheumatology, Florida Medical Clinic PA, Zephyrhills, FL, ²Rheumatology Associates - Louisville, Louisville, KY, ³Community Rheumatology, Noblesville, IN, ⁴Crescendo Bioscience, Inc, South San Francisco, CA, ⁵Joiner Associates LLC, Madison, WI
Background/Purpose: Population management (PM) is required for reducing the burdens of chronic diseases, including RA. PM depends on standardizing disease activity assessment (DAA) and coordinating…
Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Proton Rahman¹, Saeed Shaikh², Michael Starr³, William Bensen⁴, Denis Choquette⁵, Wojciech Olszynski⁶, Maqbool Sheriff⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Susan Otawa¹⁰, Francois Nantel¹¹, Vincent Letourneau¹¹ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²McMaster University, Hamilton, ON, Canada, ³Montreal General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸Université de Montréal, Montreal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…
Abstract Number: 583 • 2014 ACR/ARHP Annual Meeting
What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
Proton Rahman¹, Michel Zummer², Wojciech Olszynski³, Majed Khraishi⁴, Dalton Sholter⁵, Rafat Faraawi⁶, William Bensen⁷, Milton Baker⁸, Andrew Chow⁹, Julie Vaillancourt¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J Lehman¹², Susan Otawa¹² and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Université de Montréal, Montreal, QC, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease…
Abstract Number: 369 • 2014 ACR/ARHP Annual Meeting
Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP) in Canadian Patients with Rheumatoid Arthritis
William G Bensen¹, Wynn Bensen², Melissa Deamude², Cynthia Mech³, Robert Bensen⁴, Arthur N. Lau⁵ and Alpesh Shah⁶, ¹St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ²Dr William G Bensen Medicine Professional Corp, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁴Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ⁵Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Epidemiology and Biostatistics, University of Western Ontario, MSc in Clinical Epidemiology, University of Western Ontario, London, ON, Canada
Background/Purpose: Measuring disease activity in Rheumatoid Arthritis (RA) remains an elusive goal. Both DAS and CDAI have an inherent weakness because similar numbers can result…
Abstract Number: 2975 • 2014 ACR/ARHP Annual Meeting
Residual Large Joint Synovitis By Power Doppler Ultrasonography Is Associated with Higher Disease Activity and Significant Impact of Disease in Multi-Ethnic Asian Patients with Established Rheumatoid Arthritis
Yu Xiao Guo¹, Manjari Lahiri^2,3 and Peter Cheung^2,3, ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Division of Rheumatology, National University Hospital, Singapore, Singapore
Background/Purpose Regular monitoring of disease activity with appropriate modification of disease-modifying anti-rheumatic drug (DMARD) therapy results in improved radiographic and functional outcomes in patients with…
Abstract Number: 2578 • 2014 ACR/ARHP Annual Meeting
Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort.
Cristina Fernández-Carballido¹, Victoria Navarro-Compán², Mireia Moreno³, Xavier Juanola⁴, Juan Mulero⁵ and Eugenio De Miguel⁶, ¹Rheumatology, University General Hospital Elda, Elda (Alicante), Spain, ²Rheumatology, University Hospital La Paz and Leiden University Medical Center, Madrid, Spain, ³Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ⁵Rheumatology, University Hospital Puerta de Hierro, Majadahonda (Madrid), Spain, ⁶Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain
Background/Purpose : Main objective: to describe health related quality of life (HRQoL), physical function (PF) and spinal mobility (SM) in patients with early axial Spondyloarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].